{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:41:12Z","timestamp":1791844872838,"version":"4.3.4"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Therapeutic antibodies have become a major strategy to treat oncologic diseases. For chronic lymphocytic leukemia, antibodies against CD20 are used to target and elicit cytotoxic responses against malignant B cells. However, efficacy is often compromised due to a suppressive microenvironment that interferes with cellular immune responses. To overcome this suppression, agonists of pattern recognition receptors have been studied which promote direct cytotoxicity or elicit anti-tumoral immune responses. NOD2 is an intracellular pattern recognition receptor that participates in the detection of peptidoglycan, a key component of bacterial cell walls. This detection then mediates the activation of multiple signaling pathways in myeloid cells. Although several NOD2 agonists are being used worldwide, the potential benefit of these agents in the context of antibody therapy has not been explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Primary cells from healthy-donor volunteers (PBMCs, monocytes) or CLL patients (monocytes) were treated with versus without the NOD2 agonist L18-MDP, then antibody-mediated responses were assessed. In vivo, the E\u00b5-TCL1 mouse model of CLL was used to test the effects of L18-MDP treatment alone and in combination with anti-CD20 antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment of peripheral blood mononuclear cells with L18-MDP led to activation of monocytes from both healthy donors and CLL patients. In addition, there was an upregulation of activating Fc\u03b3R in monocytes and a subsequent increase in antibody-mediated phagocytosis. This effect required the NF-\u03baB and p38 signaling pathways. Treatment with L18-MDP plus anti-CD20 antibody in the E\u00b5-TCL model of CLL led to a significant reduction of CLL load, as well as to phenotypic changes in splenic monocytes and macrophages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Taken together, these results suggest that NOD2 agonists help overturn the suppression of myeloid cells, and may improve the efficacy of antibody therapy for CLL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1409333","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T09:24:58Z","timestamp":1718184298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["NOD2 activation enhances macrophage Fc\u03b3 receptor function and may increase the efficacy of antibody therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Giovanna","family":"Merchand-Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikayla F.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramasamy","family":"Santhanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Valencia-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh A.","family":"Murugesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadesh","family":"Chordia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui-Molly","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"Robledo-Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan De Dios","family":"Ruiz-Rosado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William Edgar","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susheela","family":"Tridandapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Butchar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188.2188_2188_2195","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.bloodjournal832435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202588","article-title":"Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties","volume":"190","author":"Rafiq","year":"2013","journal-title":"J Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"MAbs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MCHD-0045-2016","article-title":"The role and function of fcgamma receptors on myeloid cells","volume":"4","author":"Bournazos","year":"2016","journal-title":"Microbiol Spectr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.13.6023","article-title":"Association of the high-affinity receptor for IgG (Fc gamma RI) with the gamma subunit of the IgE receptor","volume":"90","author":"Ernst","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00223","article-title":"Multiple Variables at the Leukocyte Cell Surface Impact Fc gamma Receptor-Dependent Mechanisms","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2447","article-title":"Shaping cups into phagosomes and macropinosomes","volume":"9","author":"Swanson","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12336","article-title":"Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling","volume":"268","author":"Getahun","year":"2015","journal-title":"Immunol Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.2.618","article-title":"IgG-mediated enhancement of antibody responses is low in fc receptor \u03b3 Chain-deficient mice and increased in Fc\u03b3RII-deficient mice1","volume":"163","author":"Wernersson","year":"1999","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/DDDT","article-title":"Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC","volume":"3","author":"Natsume","year":"2009","journal-title":"Drug Design Dev Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0120","article-title":"Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions","volume":"3","author":"DiLillo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molimm.2017.11.014","article-title":"Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia","volume":"110","author":"Hanna","year":"2019","journal-title":"Mol Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.073080","article-title":"The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation","volume":"98","author":"Maffei","year":"2013","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2655.h8002655_2655_2663","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.74","article-title":"Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients","volume":"5","author":"Boissard","year":"2015","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1030","article-title":"Distinctive features of \"nurselike\" cells that differentiate in the context of chronic lymphocytic leukemia","volume":"99","author":"Tsukada","year":"2002","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.10.1325","article-title":"Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo","volume":"139","author":"Urosevic","year":"2003","journal-title":"Arch Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41598-020-80957-z","article-title":"The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent","volume":"11","author":"Cheng","year":"2021","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1888","article-title":"Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized clinical trial","volume":"4","author":"Ferris","year":"2018","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"114759","DOI":"10.1016\/j.biopha.2023.114759","article-title":"TLR8 agonist Motolimod-induced inflammatory death for treatment of acute myeloid leukemia","volume":"163","author":"Yang","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx179","article-title":"Pattern recognition receptors: immune targets to enhance cancer immunotherapy","volume":"28","author":"Shekarian","year":"2017","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.09.031","article-title":"Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer","volume":"39","author":"Sfakianos","year":"2021","journal-title":"Urol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577823","article-title":"MPL adjuvant contains competitive antagonists of human TLR4","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.161249","article-title":"Imiquimod - Its role in the treatment of cutaneous Malignancies","volume":"47","author":"Bubna","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213363","article-title":"Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells","volume":"115","author":"Liang","year":"2010","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.741233","article-title":"Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine","volume":"54","author":"Wolska","year":"2013","journal-title":"Leukemia lymphoma"},{"key":"B31","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006","article-title":"Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells","volume":"95","author":"Decker","year":"2000","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.608451","article-title":"Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia","volume":"53","author":"Zent","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2128-x","article-title":"Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation","volume":"67","author":"Ringelstein-Harlev","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2174\/157340711796817913","article-title":"Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy","volume":"7","author":"Ogawa","year":"2011","journal-title":"Curr Bioact Compd"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(74)90458-6","article-title":"Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives","volume":"59","author":"Ellouz","year":"1974","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/416194a","article-title":"RICK\/Rip2\/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems","volume":"416","author":"Kobayashi","year":"2002","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M307198200","article-title":"Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2","volume":"278","author":"Girardin","year":"2003","journal-title":"J Biol Chem"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20061704","article-title":"Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide","volume":"404","author":"Windheim","year":"2007","journal-title":"Biochem J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1521-4141","article-title":"Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists","volume":"35","author":"Fritz","year":"2005","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.16.6112","article-title":"Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide","volume":"85","author":"Shaw","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199305000-00004","article-title":"Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides","volume":"13","author":"Hoedemakers","year":"1993","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00297.2012","article-title":"NLRP1 and NLRP3 inflammasomes are essential for distinct outcomes of decreased cytokines but enhanced bacterial killing upon chronic Nod2 stimulation","volume":"304","author":"Hedl","year":"2013","journal-title":"Am J Of Physiol Gastrointestinal And Liver Physiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.08.009","article-title":"Triggering of NOD2 receptor converts inflammatory ly6C(high) into ly6C(low) monocytes with patrolling properties","volume":"20","author":"Lessard","year":"2017","journal-title":"Cell Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2165\/11204910-000000000-00000","article-title":"Mifamurtide: a review of its use in the treatment of osteosarcoma","volume":"12","author":"Frampton","year":"2010","journal-title":"Paediatr Drugs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.intimp.2017.11.036","article-title":"NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases","volume":"54","author":"Pashenkov","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900885","article-title":"Activation of the intracellular pattern recognition receptor NOD2 promotes acute myeloid leukemia (AML) cell apoptosis and provides a survival advantage in an animal model of AML","volume":"204","author":"Buteyn","year":"2020","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/med.21557","article-title":"Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy","volume":"39","author":"Nabergoj","year":"2019","journal-title":"Medicinal Res Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.08.003","article-title":"Convergence of innate immunity and insulin resistance as evidenced by increased nucleotide oligomerization domain (NOD) expression and signaling in monocytes from patients with type 2 diabetes","volume":"64","author":"Shiny","year":"2013","journal-title":"Cytokine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504271103","article-title":"Internalization and phagosome escape required for Francisella to induce human monocyte IL-1beta processing and release","volume":"103","author":"Gavrilin","year":"2006","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900059","article-title":"CD31 acts as a checkpoint molecule and is modulated by fcgammaR-mediated signaling in monocytes","volume":"203","author":"Merchand-Reyes","year":"2019","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087623","article-title":"Inhibition of BET proteins regulates fcgamma receptor function and reduces inflammation in rheumatoid arthritis","volume":"24","author":"Shankar","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626754","article-title":"Mechanisms of PD-L1\/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100931","article-title":"Disruption of nurse-like cell differentiation as a therapeutic strategy for chronic lymphocytic leukemia","volume":"209","author":"Merchand-Reyes","year":"2022","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02515","article-title":"Early growth response gene-2 is essential for M1 and M2 macrophage activation and plasticity by modulation of the transcription factor CEBPbeta","volume":"9","author":"Veremeyko","year":"2018","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145342","article-title":"Novel markers to delineate murine M1 and M2 macrophages","volume":"10","author":"Jablonski","year":"2015","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e82623","DOI":"10.1371\/journal.pone.0082623","article-title":"Nod2 activates NF-kB in CD4+ T cells but its expression is dispensable for T cell-induced colitis","volume":"8","author":"Zanello","year":"2013","journal-title":"PloS One"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326355","article-title":"Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets","volume":"118","author":"Wong","year":"2011","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.9.3593.bloodjournal8793593","article-title":"FcR \u03b3-chain is essential for both surface expression and function of human fc\u03b3RI (CD64) in vivo","volume":"87","author":"van Vugt","year":"1996","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.1.247","article-title":"Different roles for the Fc epsilon RI gamma chain as a function of the receptor context","volume":"181","author":"Paolini","year":"1995","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1038\/s41598-022-07804-1","article-title":"Valosin-containing protein-regulated endoplasmic reticulum stress causes NOD2-dependent inflammatory responses","volume":"12","author":"Ghalandary","year":"2022","journal-title":"Sci Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-019-0252-7","article-title":"IL-1alpha and IL-1beta promote NOD2-induced immune responses by enhancing MAPK signaling","volume":"99","author":"Li","year":"2019","journal-title":"Lab Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2669","article-title":"Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis","volume":"14","author":"Yang","year":"2013","journal-title":"Nat Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404017","article-title":"TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state","volume":"20","author":"Herling","year":"2006","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4136","article-title":"Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow","volume":"69","author":"Hartmann","year":"2009","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.387","article-title":"Increased FcgammaRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients","volume":"36","author":"Burgess","year":"2017","journal-title":"Oncogene"},{"key":"B70","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-135160","article-title":"Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV","volume":"112","author":"Minard-Colin","year":"2008","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd6167","article-title":"Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis","volume":"7","author":"Grandjean","year":"2021","journal-title":"Sci Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.007218","article-title":"RIP2 promotes FcgammaR-mediated reactive oxygen species production","volume":"294","author":"Shehat","year":"2019","journal-title":"J Biol Chem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2756","article-title":"Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma","volume":"50","author":"Rosenzweig","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B75","article-title":"Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine","volume":"49","author":"Kleinerman","year":"1989","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.8.1310","article-title":"Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration","volume":"10","author":"Kleinerman","year":"1992","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.2174\/156800906776056473","article-title":"Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma","volume":"6","author":"Nardin","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"B78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1756-9966-33-27","article-title":"Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-gamma","volume":"33","author":"Pahl","year":"2014","journal-title":"J Exp Clin Cancer Res Cr"},{"key":"B79","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/09629359990306","article-title":"Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides","volume":"8","author":"Dieter","year":"1999","journal-title":"Mediators Inflammation"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00480","article-title":"Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors","volume":"18","author":"Ntoufa","year":"2012","journal-title":"Mol Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.031","article-title":"Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and\/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate","volume":"23","author":"Meyers","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2020.21.3.715","article-title":"Muramyl tripeptide plus chemotherapy reduces metastasis in non-metastatic osteosarcoma: A single-center experience","volume":"21","author":"Tacyildiz","year":"2020","journal-title":"Asian Pacific J Cancer Prevention: APJCP"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1409333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T09:25:04Z","timestamp":1718184304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1409333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2024.1409333"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1409333","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"article-number":"1409333"}}